JP2020527355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527355A5 JP2020527355A5 JP2020502992A JP2020502992A JP2020527355A5 JP 2020527355 A5 JP2020527355 A5 JP 2020527355A5 JP 2020502992 A JP2020502992 A JP 2020502992A JP 2020502992 A JP2020502992 A JP 2020502992A JP 2020527355 A5 JP2020527355 A5 JP 2020527355A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- cdr2
- cdr3
- indicated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023065086A JP2023083385A (ja) | 2017-07-17 | 2023-04-12 | 結合タンパク質１ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762533546P | 2017-07-17 | 2017-07-17 | |
| US62/533,546 | 2017-07-17 | ||
| US201762596694P | 2017-12-08 | 2017-12-08 | |
| US62/596,694 | 2017-12-08 | ||
| PCT/US2018/042532 WO2019018426A1 (en) | 2017-07-17 | 2018-07-17 | BINDING PROTEINS 1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065086A Division JP2023083385A (ja) | 2017-07-17 | 2023-04-12 | 結合タンパク質１ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527355A JP2020527355A (ja) | 2020-09-10 |
| JP2020527355A5 true JP2020527355A5 (enExample) | 2021-08-26 |
| JP7690285B2 JP7690285B2 (ja) | 2025-06-10 |
Family
ID=65015294
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502992A Active JP7690285B2 (ja) | 2017-07-17 | 2018-07-17 | 結合タンパク質１ |
| JP2023065086A Pending JP2023083385A (ja) | 2017-07-17 | 2023-04-12 | 結合タンパク質１ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023065086A Pending JP2023083385A (ja) | 2017-07-17 | 2023-04-12 | 結合タンパク質１ |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US11613590B2 (enExample) |
| EP (1) | EP3655432A4 (enExample) |
| JP (2) | JP7690285B2 (enExample) |
| CN (1) | CN111094338A (enExample) |
| AU (1) | AU2018302110B2 (enExample) |
| CA (2) | CA3300582A1 (enExample) |
| IL (1) | IL272064A (enExample) |
| WO (2) | WO2019018426A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2744840T3 (es) | 2011-04-01 | 2020-02-26 | Univ Yale | Anticuerpos anti-ADN que penetran en las células y usos de los mismos para inhibir la reparación del ADN |
| US12486318B2 (en) | 2016-06-15 | 2025-12-02 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| WO2017218825A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| WO2019152806A1 (en) * | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for enhancing nuclear translocation |
| US20210340279A1 (en) * | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
| US12485180B2 (en) | 2019-08-30 | 2025-12-02 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| IL301014A (en) | 2020-08-31 | 2023-05-01 | Univ Yale | Compositions and methods for delivery of nucleic acids to cells |
| CN117295753A (zh) | 2020-12-04 | 2023-12-26 | 基那奥生物公司 | 用于将核酸递送到细胞的组合物和方法 |
| IL305515A (en) | 2021-03-03 | 2023-10-01 | Univ Yale | Preparations and methods for the treatment of skeletal muscle disease |
| US20240226311A1 (en) * | 2021-05-25 | 2024-07-11 | Transmab Pty Ltd | Improved immunoglobulin II |
| US20240226316A1 (en) * | 2021-05-25 | 2024-07-11 | Transmab Pty Ltd | Improved immunoglobulin I |
| IL309662A (en) | 2021-07-02 | 2024-02-01 | Univ Yale | Compositions and methods for treating cancers |
| EP4395832A1 (en) | 2021-08-31 | 2024-07-10 | Yale University | Compositions and methods for treating cancers |
| US20250051406A1 (en) * | 2021-12-15 | 2025-02-13 | The Trustees Of Indiana University | Cell targeting compositions and methods |
| US20250170259A1 (en) | 2022-03-03 | 2025-05-29 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| JP2025507840A (ja) * | 2022-03-03 | 2025-03-21 | イエール ユニバーシティ | ヒト化３ｅ１０抗体、そのバリアント、及び抗原結合断片 |
| US20250161484A1 (en) | 2022-03-03 | 2025-05-22 | Yale University | Compositions and methods for treating disease |
| EP4584292A1 (en) | 2022-09-09 | 2025-07-16 | Yale University | Proteolysis targeting antibodies and methods of use thereof |
| CN120787163A (zh) | 2022-12-27 | 2025-10-14 | 耶鲁大学 | 抗体药物缀合物 |
| EP4655007A1 (en) | 2023-01-23 | 2025-12-03 | Yale University | Antibody oligonucleotide conjugates |
| EP4683674A1 (en) | 2023-03-23 | 2026-01-28 | Yale University | Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping |
| WO2025049905A1 (en) | 2023-09-01 | 2025-03-06 | Gennao Bio, Inc. | Dnase co-expression in host cells |
| WO2025090121A1 (en) * | 2023-10-27 | 2025-05-01 | Yale University | Conjugate and methods of treatment |
| WO2025097000A1 (en) | 2023-11-01 | 2025-05-08 | Yale University | Antibody-based methods for treating polycystic kidney disease |
| CN117924516B (zh) * | 2024-01-02 | 2025-07-01 | 河北神宇生物技术有限公司 | 一种提高adc药物疗效的重组蛋白及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0615662D0 (en) | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| CA2936102A1 (en) * | 2014-01-13 | 2015-07-16 | Valerion Therapeutics, Llc | Internalizing moieties |
| WO2015134607A1 (en) | 2014-03-04 | 2015-09-11 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations |
| WO2015192092A1 (en) * | 2014-06-13 | 2015-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
| EP3186278A4 (en) * | 2014-08-27 | 2018-04-04 | Valerion Therapeutics, LLC | Internalizing moieties for treatment of cancer |
| JP2017534571A (ja) | 2014-08-28 | 2017-11-24 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 抗体３ｅ１０の多価フラグメントおよびその使用方法 |
| US10383945B2 (en) * | 2015-02-18 | 2019-08-20 | The United States of America as Represented by the Department of Verterans Affairs | Methods for DNA-dependent targeting of a cell permeant antibody |
-
2018
- 2018-07-17 EP EP18835802.2A patent/EP3655432A4/en active Pending
- 2018-07-17 WO PCT/US2018/042532 patent/WO2019018426A1/en not_active Ceased
- 2018-07-17 CA CA3300582A patent/CA3300582A1/en active Pending
- 2018-07-17 CA CA3070252A patent/CA3070252A1/en active Pending
- 2018-07-17 US US16/631,418 patent/US11613590B2/en active Active
- 2018-07-17 CN CN201880054249.7A patent/CN111094338A/zh active Pending
- 2018-07-17 US US16/631,421 patent/US20200216568A1/en not_active Abandoned
- 2018-07-17 AU AU2018302110A patent/AU2018302110B2/en active Active
- 2018-07-17 JP JP2020502992A patent/JP7690285B2/ja active Active
- 2018-07-17 WO PCT/US2018/042534 patent/WO2019018428A1/en not_active Ceased
-
2020
- 2020-01-15 IL IL272064A patent/IL272064A/en unknown
-
2022
- 2022-12-20 US US18/069,124 patent/US20240052063A1/en active Pending
-
2023
- 2023-02-03 US US18/164,444 patent/US12312417B2/en active Active
- 2023-04-12 JP JP2023065086A patent/JP2023083385A/ja active Pending
-
2025
- 2025-04-22 US US19/186,381 patent/US20250376540A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502271A5 (enExample) | ||
| JP2022101693A5 (enExample) | ||
| JP2023548443A5 (enExample) | ||
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| JP2021508469A5 (enExample) | ||
| JP2021534762A5 (enExample) | ||
| JP2021527714A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| JP2013527761A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2021524267A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2017529838A5 (enExample) | ||
| JP2019513018A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| RU2010141584A (ru) | Антитело против csf-1r | |
| JP2023543031A5 (enExample) | ||
| FI3856775T3 (fi) | Kimeerinen antigeenireseptori | |
| JP2011207882A5 (enExample) | ||
| JP2021508707A5 (enExample) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2023549537A5 (enExample) |